Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) announced a series of appointments on Thursday designed to strengthen the CBD drug discovery company’s executive team.
The Ottawa-based firm has named Graham Wood as its new chief operating officer, replacing Steeve Neron, who is transitioning into the chief commercial officer role.
In addition, the company is adding two seasoned healthcare executives to its board of directors in the form of former McKesson Canada senior advisor Dale Weil and Brent Norton, a medical doctor and venture partner with Lumira Ventures.
"We are pleased to welcome Dale and Brent to the Tetra Board and Graham to our executive team,” Tetra Bio-Pharma chairman Bill Cheliak said in a statement on the appointments.
“Guy and I feel confident that we have selected two highly qualified board members who will bring additional knowledge, talent, experiences, and perspective to the Board. Their leadership and commitment will be invaluable as we advance many of our clinical assets to commercialization.”
New COO Graham Wood holds a PhD from McGill University and spent over 21 years in the pharmaceutical industry, developing an expertise in inhalation clinical research. Wood spent five years at leading clinical research facility Altasciences, where he conducted over 40 studies on different cannabinoid products including Tetra’s own QIXLEEF.
Tetra CEO Guy Chamberland told investors the new COO will be actively involved in the firm’s inhalation programs: “(Wood) will support Tetra's clinical team and be backed by our highly experienced pharmaceutical compliance unit.”
Chamberland said. “The addition of Graham will provide me and the Board with the oversight required to manage our clinical program."
Tetra is advancing a US Foord & Drug Administration and a Health Canada-approved cannabinoid-based clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas